Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications
Over the past ten years, sorafenib, a multikinase inhibitor, has been the only systemic agent approved for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). Whereas only recently lenvatinib was shown to be noninferior to sorafenib, in terms of survival, all other age...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BioExcel Publishing Ltd
2018-06-01
|
| Series: | Drugs in Context |
| Subjects: | |
| Online Access: | https://www.drugsincontext.com/regorafenib-in-hepatocellular-carcinoma-latest-evidence-and-clinical-implications |